A Webinar on Future Prospects of Pharmacovigilance & Drug Safety on 11.07.2020
Know About Prevention of Adverse Effects of Medicines: Register Now
The Department of Pharmaceutical Technology of Maulana Abul Kalam Azad University of Technology (MAKAUT), West Bengal, India will be organizing a Webinar on "Future Prospects of Pharmacovigilance & Drug Safety" on 11.07.2020.
This Webinar assumes much significance in the context of the CORONA Pandemic. So, Registear now to have insights into the topic from eminent speskers.
It will be organized by:
Dr. C.M Hossain,
HoD-Department of Pharmaceutical Technology, MAKAUT, WB.
The eminent speakers are: Hon'ble Vice Chancellor of MAKAUT Prof. (Dr.) Saikat Maitra, Mr. Saikat Biswas Global Head-Life Sciences Digital Operations of Wiporo Ltd, Prof. Pranabesh Chakraborty Director-Food, Pharmaceutical and Medical Science & Technology, MAKAUT, WB and
Dr. C. M. Hossain HoD-Department of Pharmaceutical Technology, MAKAUT, WB.
Dr. C. M. Hossain HoD-Department of Pharmaceutical Technology, MAKAUT, WB.
It may be mentioned at this point that, Pharmacovigilance is defined by the World Health Organization as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
Adverse drug reactions experienced with use of a medicinal product may result in significant morbidity and mortality. The ultimate goal of pharmacovigilance is to ensure safe use of medicines, minimizing the risks related to the medicinal product and maximizing the benefits. During development of a medicinal product, it undergoes animal testing and establishes its safety and efficacy in human beings before permission to market is granted. However, clinical trials are conducted on a smaller number of patients, ranging to a few thousand, and excluding special populations, e.g., children, pregnant and lactating women, and geriatric patients. Data generated during clinical trials will provide information about the common adverse events but more rare adverse events may not be encountered. Therefore, it is important to monitor safety during the postapproval period and to arrive at the actual risk-benefit profile of the medicinal product and take necessary measures to minimize risks.
Registration Open now:
Register in advance for this webinar:
After registering, you will receive a confirmation email containing information about joining the webinar.
Comments